HopeStage
Back to overview

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Topics
More filters
27277studies shown
Showing 4,117-4,128 of 27,277
Drug study icon
RecruitingACTRN12605000394640

Treatment of Schizophrenia with Aripiprazole. A one year study.

Official study title

Treatment of Schizophrenia with Aripiprazole. A one year open-label study examining an ultraslow switchover regime to minimise relapse and withdrawal symptoms.

Location not clearly listed
SchizophreniaInterventional study
Countries
Sponsor
Associate Professor Krishna Vaddadi
Drug study icon
RecruitingNCT06518720

A feasibility study of psilocybin therapy for nerve pain and depression

About this title

Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND)

Read the official source — NCT06518720
Official study title

Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND): An Open-Label Clinical Trial

In Toronto
DepressionMedication studyAges 18–65
Countries
Canada
Sponsor
Centre for Addiction and Mental Health (Hospital / academic medical center)
Behavioral study icon
RecruitingNCT06722781

Personalized online group therapy for anxiety and depression

About this title

Trial of an Online Group Psychotherapy Intervention for Common Mental Health Disorders

Read the official source — NCT06722781
Official study title

UpLift-X Trial 1: A Cluster Factorial Randomised Controlled Trial of Digitally-enabled Group Psychotherapy for Common Mental Disorders

In Exeter
Anxiety, DepressionBehavioural studyAges 17+
Countries
United Kingdom
Sponsor
Rotherham Doncaster and South Humber NHS Foundation Trust
Drug study icon
RecruitingNCT05325645

Once-weekly brexpiprazole or placebo for acute schizophrenia

About this title

Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia

Read the official source — NCT05325645
What is this study about?

Researchers are comparing OPC-34712FUM/ Brexpiprazole fumarate and placebo to find out how the approaches affect psychotic symptoms in people with schizophrenia.

In Kure-shi
SchizophreniaMedication studyAges 18–74
Countries
Japan
Sponsor
Otsuka Pharmaceutical Co., Ltd. (Pharmaceutical company)

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.